Global Ophthalmology Drugs Market to 2022 - Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period

GBI Research
150 Pages - GBI10552
$4,995.00

Summary

Ophthalmology is a therapy area that deals with the diagnosis, treatment and prevention of diseases associated with the eyes and visual system. Most eye disorders occur over a long period of time, and are initially asymptomatic or cause only a slight decrease in vision. However, over time this becomes quite marked. Ophthalmologic disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

Angiogenesis inhibitors are the most effective and most common therapies used in ophthalmology; this class of compounds has been the most commercially successful in the past decade, with products such as Eylea and Lucentis generating strong annual revenues. Although there are many generics available across the majority of ophthalmology disorders, there are a number of premium products that attract substantial revenues - in particular Eylea, Lucentis, Lumigan and Restasis. The report focuses on five key indications within ophthalmology: glaucoma, age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy and dry eye syndrome. There are currently no therapeutic options available for the treatment of dry AMD, increasing the need for extensive R&D within this area.  

Although there is a high degree of failure and uncertainty within the R&D of ophthalmology drugs, the number of drugs in the pipeline is very high, at 734. The majority of pipeline products are novel active pharmaceutical ingredients, with only a small proportion of products being either generics or repositioned from other indications.  This shows progression in terms of the variety of different molecules being developed as therapeutic agents within the ophthalmology pipeline. The expected growth of the ophthalmology market over the forecast period is attributed to the approval of new drugs, as well as rising prevalence.

Scope

- Global revenues for the ophthalmology market are forecast to grow at a compound annual growth rate of 9.48%, from $13.7 billion in 2015 to $26 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- The ophthalmology pipeline is large and diverse, and contains 734 products. How does the composition of the pipeline compare with that of the existing market?
- What mechanisms of action and molecule types are most commonly being trialed in pipeline products in the various key indications?
- Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
- Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
- Visualize the composition of the ophthalmology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
- Analyze the ophthalmology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenues for the ophthalmology market, globally and across the key players and product types
- Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various ophthalmology disorders.
- Identify commercial opportunities in the urological cancer deals landscape by analyzing trends in licensing and co-development deals

'

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Therapy Area Introduction 9
2.1.1 Glaucoma 9
2.1.2 Age-Related Macular Degeneration 9
2.1.3 Diabetic Macular Edema 10
2.1.4 Diabetic Retinopathy 10
2.1.5 Dry Eye Syndrome 10
2.2 Symptoms 11
2.3 Etiology and Pathophysiology 13
2.3.1 Etiology 13
2.3.2 Pathophysiology 15
2.4 Co-morbidities and Complications 18
2.5 Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 19
2.5.1 Glaucoma 20
2.5.2 Age-Related Macular Degeneration 21
2.5.3 Diabetic Macular Edema 22
2.5.4 Diabetic Retinopathy 22
2.5.5 Dry Eye Syndrome 24
2.6 Treatment 26
3 Key Marketed Products 29
3.1 Overview 29
3.2 Lucentis (ranibizumab) 29
3.3 Eylea (aflibercept) 30
3.4 Avastin (bevacizumab) 31
3.5 Restasis (cyclosporine) 32
3.6 Alphagan (brimonidine tartrate) 34
3.7 Lumigan (bimatoprost) 35
3.8 Xalatan (latanoprost) 36
4 Pipeline Landscape Assessment 38
4.1 Overview 38
4.2 Pipeline Development Landscape 38
4.3 Mechanisms of Action in the Pipeline 41
4.4 Clinical Trials 44
4.4.1 Failure Rate 44
4.4.2 Clinical Trial Duration 48
4.4.3 Clinical Trial Size 52
4.4.4 Aggregate Clinical Program Size 56
4.4.5 Conclusion 60
5 Multi-Scenario Market Forecast to 2022 61
5.1 Overall Market Size 61
5.2 Generic Penetration 62
5.3 Revenue Forecast by Molecular Target 63
5.3.1 Angiogenesis Inhibitors (VEGF/PlGF/PDGF Inhibitors) 63
5.3.2 Antihistamines (H1 Receptor) 64
5.3.3 Anti-inflammatories (Glucocorticoid Receptor/IL-1 Receptor/Prostaglandin Receptor) 65
5.3.4 IOP-Lowering (Prostaglandins/Beta Blockers/Rho Kinase Signaling Pathway) 66
5.3.5 Assessment of Key Pipeline Products 66
6 Company Analysis and Positioning 72
6.1 Revenue and Market Share Analysis by Company 73
6.1.1 Novartis - Will Pipeline Product Approvals Offset the Patent Expiry of Lucentis? 78
6.1.2 Bayer - Growing Revenues for Eylea Set to Increase Bayer’s Revenue 79
6.1.3 Regeneron - Growing Revenues for Eylea Will Make it the Top Selling Ophthalmology Drug 80
6.1.4 Roche - Gradual Decline in Revenues Due to Lucentis Patent Expiries and Uptake of Generics 81
6.1.5 Ophthotech - Pipeline Product Approval will Result in Blockbuster Status Within the Forecast Period 82
6.1.6 Spark Therapeutics - Pipeline Product Approval to Resulting in Large Revenues in a Short Space of Time 83
6.1.7 Santen - Patent Expiration of Eylea to Cause Gradual Decline in Revenue 83
6.2 Company Landscape 85
6.3 Marketed and Pipeline Portfolio Analysis 86
7 Strategic Consolidations 89
7.1 Licensing Deals 89
7.1.1 Deals by Region, Year and Value 89
7.1.2 Deals by Stage of Development and Value 91
7.1.3 Deals by Molecule Type, Mechanism of Action and Value 92
7.1.4 Table for Licensing Deals Valued Above $100m 94
7.2 Co-development Deals 95
7.2.1 Deals by Region, Year and Value 95
7.2.2 Deals by Stage of Development and Value 97
7.2.3 Deals by Molecule Type, Mechanism of Action and Value 98
7.2.4 Table for Co-development Deals Valued Above $100m 99
8 Appendix 100
8.1 References 100
8.2 Table of All Clinical Stage Pipeline Products 108
8.3 Abbreviations 147
8.4 Disease List 147
8.5 Methodology 148
8.5.1 Coverage 148
8.5.2 Secondary Research 148
8.5.3 Market Size and Revenue Forecasts 148
8.5.4 Pipeline Analysis 149
8.5.5 Competitive Landscape 149
8.6 Contact Us 150
8.7 Disclaimer 150

1.1 List of Tables
Table 1: Ophthalmology Disease Therapeutics Market, Symptoms of Glaucoma, AMD, DME, DR and DES 12
Table 2: Ophthalmology Disease Therapeutics Market, Etiology of Glaucoma, AMD, DME, DR and DES 14
Table 3: Ophthalmology Disease Therapeutics Market, Complications associated with glaucoma, AMD, DR and DES 19
Table 4: Ophthalmology, Global, Epidemiology of Ophthalmologic Disorders, 2016 19
Table 5: Ophthalmology Disease Therapeutics Market, Treatment options available for glaucoma 27
Table 6: Ophthalmology Therapeutics Market, Global, Approved Indications for Lucentis, 2016 29
Table 7: Ophthalmology Therapeutics Market, Global, Approved Indications for Eylea, 2016 30
Table 8: Ophthalmology Therapeutics Market, Global, Approved Indications for Avastin, 2016 32
Table 9: Ophthalmology Therapeutics Market, Global, Approved Indications for Restasis, 2016 33
Table 10: Ophthalmology Therapeutics Market, Global, Approved Indications for Alphagan, 2016 35
Table 11: Ophthalmology Therapeutics Market, Global, Approved Indications for Lumigan, 2016 36
Table 12: Ophthalmology Therapeutics Market, Global, Approved Indications for Xalatan, 2016 37
Table 13: Ophthalmology, Global, Annual Revenue Forecast for key Products ($bn), 2015-2022 62
Table 14: Ophthalmology Therapeutics Market, Global, Forecast Revenues by Company, 2015-2022 74
Table 15: Ophthalmology Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016 94
Table 16: Ophthalmology Therapeutics Market, Global, Co-Development Deals Valued Above $100m, 2006-2015 99
Table 17: Ophthalmology, Global, Table of all Clinical Stage Pipeline Products, 2016 108

1.2 List of Figures
Figure 1: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Glaucoma (millions), 2015-2022 20
Figure 2: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Age-Related Macular Degeneration (millions), 2015-2022 21
Figure 3: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Diabetic Macular Edema (millions), 2015-2022 22
Figure 4: Ophthalmology, Seven Major Markets, Epidemiology Patterns for Diabetic Retinopathy (millions), 2015-2022 23
Figure 5: Ophthalmology, Global, Epidemiology Patterns for Dry Eye Syndrome (millions), 2015-2022 25
Figure 6: Ophthalmology Therapeutics Market, Global, Annual Revenue for Lucentis ($bn), 2006-2022 30
Figure 7: Ophthalmology Therapeutics Market, Global, Annual Revenue for Eylea ($bn), 2006-2022 31
Figure 8: Ophthalmology Therapeutics Market, Global, Annual Revenue for Avastin ($bn), 2006-2022 32
Figure 9: Ophthalmology Therapeutics Market, Global, Annual Revenue for Restasis ($bn), 2006-2022 34
Figure 10: Ophthalmology Therapeutics Market, Global, Annual Revenue for Alphagan ($m), 2006-2022 35
Figure 11: Ophthalmology Therapeutics Market, Global, Annual Revenue for Lumigan ($bn), 2006-2022 36
Figure 12: Ophthalmology Therapeutics Market, Global, Annual Revenue for Xalatan ($m), 2006-2022 37
Figure 13: Ophthalmology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016 38
Figure 14: Ophthalmology Therapeutics Market, Global, Pipeline for Ophthalmology by Stage of Development, Molecule Type and Program Type, 2016 39
Figure 15: Breakdown of Biologics in Ophthalmology Pipeline, 2016 40
Figure 16: Ophthalmology Therapeutics Market, Global, Pipeline for Key Ophthalmology Indications by Stage of Development, 2016 41
Figure 17: Ophthalmology Therapeutics Market, Pipeline by Mechanism of Action (%), 2016 42
Figure 18: Ophthalmology Therapeutics Market, Global, Pipeline for Key Ophthalmology Indications by Mechanism of Action, 2016 43
Figure 19: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016 44
Figure 20: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016 45
Figure 21: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016 46
Figure 22: Ophthalmology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016 47
Figure 23: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016 48
Figure 24: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016 49
Figure 25: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016 50
Figure 26: Ophthalmology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016 51
Figure 27: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006-2016 52
Figure 28: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2015 53
Figure 29: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016 54
Figure 30: Ophthalmology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016 55
Figure 31: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2016 56
Figure 32: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016 57
Figure 33: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2015 58
Figure 34: Ophthalmology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016 59
Figure 35: Ophthalmology, Global, Market Size ($bn), 2015-2022 61
Figure 36: Ophthalmology, Global, Annual Revenue Forecast for Key Products ($m), 2015-2022 63
Figure 37: Ophthalmology, Global, Annual Revenue Forecast for Angiogenesis Inhibitors ($bn), 2015-2022 64
Figure 38: Ophthalmology, Global, Annual Revenue Forecast for Antihistamines ($m), 2015-2022 65
Figure 39: Ophthalmology, Global, Annual Revenue Forecast for Anti-inflammatories ($m), 2015-2022 65
Figure 40: Ophthalmology, Global, Annual Revenue Forecast for IOP-Lowering Drugs ($bn), 2015-2022 66
Figure 41: Ophthalmology, Global, Revenue Forecast for Fovista($m), 2017-2022 67
Figure 42: Ophthalmology, Global, Revenue Forecast for SPK-RPE65 ($m), 2017-2022 68
Figure 43: Ophthalmology, Global, Revenue Forecast for Lampalizumab ($m), 2017-2022 69
Figure 44: Ophthalmology, Global, Revenue Forecast for Rhopressa ($m), 2017-2022 70
Figure 45: Ophthalmology, Global, Revenue Forecast for Roclatan ($m), 2018-2022 71
Figure 46: Ophthalmology Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022 72
Figure 47: Ophthalmology  Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022 75
Figure 48: Ophthalmology, Global, Companies by Compound Annual Growth Rate (%), 2014-2022 76
Figure 49: Ophthalmology, Global, Revenues by Product Type, 2014-2022 77
Figure 50: Ophthalmology, Global, Novartis Annual Revenue Forecast ($m), 2015-2022 78
Figure 51: Ophthalmology, Global, Bayer Annual Revenue Forecast ($m), 2015-2022 79
Figure 52: Ophthalmology, Global, Regeneron Annual Revenue Forecast ($m), 2015-2022 80
Figure 53: Ophthalmology, Global, Roche Annual Revenue Forecast ($m), 2015-2022 81
Figure 54: Ophthalmology, Global, Ophthotech Annual Revenue Forecast ($m), 2015-2022 82
Figure 55: Ophthalmology, Global, Spark Therapeutics Annual Revenue Forecast ($m), 2015-2022 83
Figure 56: Ophthalmology, Global, Santen Therapeutics Annual Revenue Forecast ($m), 2015-2022 84
Figure 57: Ophthalmology, Global, Companies by Type, 2016 85
Figure 58: Ophthalmology, Global, High-Activity and Late-Stage Pipeline Developers by Level of Ophthalmology Specialization, 2016 86
Figure 59: Ophthalmology, Global, Proportion of Total Company Revenue Attributed to Ophthalmology, 2015-2022 87
Figure 60: Ophthalmology Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Ophthalmology, Top Four Companies ($bn), 2015-2022 88
Figure 61: Ophthalmology, Global, Licensing Deals, 2006-2016 90
Figure 62: Ophthalmology Global, Licensing Deals by Indication and Value, 2006-2016 91
Figure 63: Ophthalmology, Global, Licensing Deals, 2006-2016 92
Figure 64: Ophthalmology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2016 93
Figure 65: Ophthalmology, Global, Co-development Deals, 2006-2016 96
Figure 66: Ophthalmology, Global, Co-development Deals, 2006-2016 97
Figure 67: Ophthalmology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016 98

$4,995.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports